Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vaginal DHEA vs Estradiol for Dyspareunia in VVA
NCT05586711Phase 4Completed
- Start
- Dec 2020
- Primary completion
- Dec 2024
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dehydroepiandrosterone in Vulvovaginal atrophy (VVA) (2 arms). Primary endpoint: Change in dyspareunia (VASQ section 1) at 12 weeks. Started Dec 2020; status: completed.
02
Drugs
dehydroepiandrosterone
03
Conditions
Vulvovaginal atrophy (VVA)
Beyond the preview
Go deeper on NCT05586711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05586711.